Participants 112 159 7
patients with untreated acute myeloid leukemia.
Participants 414 555 3
In 1996, survival data were updated from three prospective, randomized comparisons of idarubicin and daunorubicin that began in 1984 and 1985
Participants 557 710 5
These were trials of the Memorial Sloan-Kettering Cancer Center (MSKCC), the U.S. Multicenter Study Group, and the Southeastern Cancer Study Group (SEG).
